These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1642562)

  • 21. Effect of immunization on herpes simplex virus type 1 latent infection in the trigeminal ganglion.
    Kramer M; Riley J; Spoering A; Coen D; Knipe D
    Curr Eye Res; 2003; 26(3-4):185-94. PubMed ID: 12815546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.
    McLean CS; Ni Challanáin D; Duncan I; Boursnell ME; Jennings R; Inglis SC
    Vaccine; 1996 Jul; 14(10):987-92. PubMed ID: 8873393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delivery of pseudorabies virus envelope antigens enclosed in immunostimulating complexes (ISCOMs); elicitation of neutralizing antibody and lymphoproliferative responses in swine and protection in mice.
    Tulman ER; Garmendia AE
    Vaccine; 1994 Nov; 12(14):1349-54. PubMed ID: 7856303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection.
    Ghiasi H; Cai S; Nesburn AB; Wechsler SL
    Virology; 1996 Oct; 224(1):330-3. PubMed ID: 8862430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8
    Srivastava R; Khan AA; Chilukuri S; Syed SA; Tran TT; Furness J; Bahraoui E; BenMohamed L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic vaccination against HSV-2: influence of vaccine formulation on immune responses and protection in mice.
    Mohamedi SA; Heath AW; Jennings R
    Vaccine; 2000 Mar; 18(17):1778-92. PubMed ID: 10699326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
    Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
    Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restriction of latent herpes virus infection in rabbits immunized with subviral herpes simplex virus vaccine.
    Rajcáni J; Kutinová L; Vonka V
    Acta Virol; 1980 May; 24(3):183-93. PubMed ID: 6107035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice.
    Hendricks RL; Tumpey TM; Finnegan A
    J Immunol; 1992 Nov; 149(9):3023-8. PubMed ID: 1401927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral response to HSV-1 subunit vaccines--a statistical analysis.
    Simms JR; Heath AW; Richardson VJ; Jennings R
    Dev Biol Stand; 1998; 92():335-40. PubMed ID: 9554289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function.
    Walker J; Leib DA
    Vaccine; 1998 Jan; 16(1):1-5. PubMed ID: 9607001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate and acquired immunity to herpes simplex virus type 1.
    Halford WP; Veress LA; Gebhardt BM; Carr DJ
    Virology; 1997 Sep; 236(2):328-37. PubMed ID: 9325240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulation of experimental murine herpes simplex keratitis: I. UV-HSV protection.
    Thompson P; Wells PA; Sandstrom IK; Opremcak EM; Millin JA; Daigle JA; Foster CS
    Curr Eye Res; 1988 Nov; 7(11):1043-9. PubMed ID: 2854036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs.
    Ghazi HO; Potter CW; Smith TL; Jennings R
    J Med Microbiol; 1995 Jan; 42(1):53-61. PubMed ID: 7739026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Herpes Simplex Virus 1 Mutant with Point Mutations in
    Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.
    Dalai SK; Pesnicak L; Miller GF; Straus SE
    J Neurovirol; 2002 Feb; 8(1):35-44. PubMed ID: 11847590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines.
    Osorio Y; Cohen J; Ghiasi H
    Invest Ophthalmol Vis Sci; 2004 Feb; 45(2):506-14. PubMed ID: 14744892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and potential application of ISCOMs in veterinary medicine.
    Morein B; Hu KF; Abusugra I
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.